ORLANDO, FL, USA (UroToday.com) - Previous retrospective review of SWOG-9346 showed that failure to achieve 7 month PSA of ≤ 4 ng/mL is associated with negative effects on overall survival. This was associated with several clinicopathologic parameters including pretreatment PSA, age, presence of bone pain, Gleason score, and performance status.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Tyler Buckley, et al. sought to identify whether pretreatment testosterone level was associated with lack of adequate PSA response after starting ADT. They studied 54 patients with similar baseline characteristics to patients in SWOG-9346. Twenty-five percent of the patients did not achieve a PSA ≤ 4 ng/mL. Baseline serum testosterone, when used as a continuous variable, was indeed negatively correlated with failure to achieve PSA ≤ 4 ng/mL. This suggests that metastatic patients with low testosterone levels may already have some degree of castration resistance, leading the investigators to hypothesize that newly metastatic hormone sensitive prostate cancer might be best treated with androgen biosynthesis blockade.
Presented by Tyler Howard Buckley, Shiven B. Patel, Srinivas Kiran Tantravahi, Julia A. Batten, David D. Stenehjem, Anitha Alex, and Neeraj Agarwal at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Hunstman Cancer Institute, Salt Lake City, UT; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Reported by Phillip Abbosh, MD, PhD, medical writer for UroToday.com